Details of the Drug Combination

General Information of Drug Combination (ID: DC62ZFQ)

Drug Combination Name
GS4071 Enoxacin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs GS4071   DMG0OUD Enoxacin   DMYTE6L
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 11.67
Bliss Independence Score: 11.67
Loewe Additivity Score: 22.54
LHighest Single Agent (HSA) Score: 22.54

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of GS4071
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
GS4071 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Influenza Neuraminidase (Influ NA) TT50QJ3 NRAM_I33A0 Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Enoxacin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [3]
Urinary tract infection GC08 Approved [4]
Enoxacin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Enoxacin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [6]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [7]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
3 Enoxacin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.
5 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
6 Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
7 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.